Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Grandville, MI
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Grandville, MI
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Benson, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Benson, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Chapel Hill, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Farmville, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Farmville, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Greenville, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Greenville, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Morrisville, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Morrisville, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Raleigh, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Wilson, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Wilson, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Wilson, NC
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Wilson, NC
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Cincinnati, OH
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Kettering, OH
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Kettering, OH
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Marion, OH
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Marion, OH
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Oklahoma City, OK
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Portland, OR
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Portland, OR
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Providence, RI
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Providence, RI
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Houston, TX
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Salt Lake City, UT
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Norfolk, VA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Seattle, WA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Vancouver,
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Vancouver,
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
North Massapequa, NY
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
North Massapequa, NY
Click here to add this to my saved trials
Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans
Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans.
Status: Enrolling
Updated:  12/31/1969
Jean Mayer Human Nutrition Research Center on Aging
mi
from
Boston, MA
Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans
Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans.
Status: Enrolling
Updated: 12/31/1969
Jean Mayer Human Nutrition Research Center on Aging
mi
from
Boston, MA
Click here to add this to my saved trials
Validating the "Foods for Health" Portfolio of Functional Food Products
Validating the "Foods for Health" Portfolio of Functional Food Products: Effects on Lipid and Blood Glucose Management in Individuals Intolerant of Statin (HMG-CoA Reductase Inhibitor) Therapy
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Validating the "Foods for Health" Portfolio of Functional Food Products
Validating the "Foods for Health" Portfolio of Functional Food Products: Effects on Lipid and Blood Glucose Management in Individuals Intolerant of Statin (HMG-CoA Reductase Inhibitor) Therapy
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Validating the "Foods for Health" Portfolio of Functional Food Products
Validating the "Foods for Health" Portfolio of Functional Food Products: Effects on Lipid and Blood Glucose Management in Individuals Intolerant of Statin (HMG-CoA Reductase Inhibitor) Therapy
Status: Enrolling
Updated:  12/31/1969
Richardson Centre for Functional Foods and Nutraceuticals
mi
from
Winnipeg,
Validating the "Foods for Health" Portfolio of Functional Food Products
Validating the "Foods for Health" Portfolio of Functional Food Products: Effects on Lipid and Blood Glucose Management in Individuals Intolerant of Statin (HMG-CoA Reductase Inhibitor) Therapy
Status: Enrolling
Updated: 12/31/1969
Richardson Centre for Functional Foods and Nutraceuticals
mi
from
Winnipeg,
Click here to add this to my saved trials
Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients
Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients: Clinical Impact of Genetic Variation in Statin Disposition
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients
Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients: Clinical Impact of Genetic Variation in Statin Disposition
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Acute Microvascular Changes With LDL Apheresis
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Acute Microvascular Changes With LDL Apheresis
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
The CREATE Wellness Study
Multi-Component Behavioral Intervention for Complex Patients With CVD Risk. The Changing Results: Engage and Activate to Enhance Wellness (CREATE Wellness) Study
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente San Jose Sabrina Wood, BA (510) 891-3551 Sabrina.B.Wood@kp.org
mi
from
San Jose, CA
The CREATE Wellness Study
Multi-Component Behavioral Intervention for Complex Patients With CVD Risk. The Changing Results: Engage and Activate to Enhance Wellness (CREATE Wellness) Study
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente San Jose Sabrina Wood, BA (510) 891-3551 Sabrina.B.Wood@kp.org
mi
from
San Jose, CA
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Cardiology and Medicine Clinic, PA
mi
from
Little Rock, AR
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Cardiology and Medicine Clinic, PA
mi
from
Little Rock, AR
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
COR Healthcare
mi
from
San Pedro, CA
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
COR Healthcare
mi
from
San Pedro, CA
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Ventura Cardiology Consultants Medical Group, Inc
mi
from
Ventura, CA
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Ventura Cardiology Consultants Medical Group, Inc
mi
from
Ventura, CA
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Wellness Clinical Research, LLC
mi
from
Hialeah Gardens, FL
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Wellness Clinical Research, LLC
mi
from
Hialeah Gardens, FL
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Maya Research Center, Inc
mi
from
Hialeah, FL
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Maya Research Center, Inc
mi
from
Hialeah, FL
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Infinity Clinical Research
mi
from
Plantation, FL
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Infinity Clinical Research
mi
from
Plantation, FL
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Midwest Heart & Vascular Specialists, LLC
mi
from
Overland Park, KA
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Midwest Heart & Vascular Specialists, LLC
mi
from
Overland Park, KA
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Krishnan Challappa M.D. PSC
mi
from
Elizabethtown, KY
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Krishnan Challappa M.D. PSC
mi
from
Elizabethtown, KY
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Long Island Heart Associates
mi
from
Mineola, NY
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Long Island Heart Associates
mi
from
Mineola, NY
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Gotham Cardiovascular Research PC
mi
from
New York, NY
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Gotham Cardiovascular Research PC
mi
from
New York, NY
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
New Bern Internal Medicine
mi
from
New Bern, NC
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
New Bern Internal Medicine
mi
from
New Bern, NC
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Detweiler Family Medicine and Associates, PC
mi
from
Lansdale, PA
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Detweiler Family Medicine and Associates, PC
mi
from
Lansdale, PA
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
Charleston Internal Medicine, Inc.
mi
from
Charleston, WV
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
Charleston Internal Medicine, Inc.
mi
from
Charleston, WV
Click here to add this to my saved trials
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated:  12/31/1969
HealthEast Clinical Trials Office
mi
from
Saint Paul, MN
Patient and Provider Assessment of Lipid Management Registry
Patient and Provider Assessment of Lipid Management Registry
Status: Enrolling
Updated: 12/31/1969
HealthEast Clinical Trials Office
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Fenofibrate Treatment in SCI
An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI
Status: Enrolling
Updated:  12/31/1969
Kessler Institute for Rehabilitation
mi
from
West Orange, NJ
Fenofibrate Treatment in SCI
An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI
Status: Enrolling
Updated: 12/31/1969
Kessler Institute for Rehabilitation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Fenofibrate Treatment in SCI
An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI
Status: Enrolling
Updated:  12/31/1969
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Fenofibrate Treatment in SCI
An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI
Status: Enrolling
Updated: 12/31/1969
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Encino, CA
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlantis, FL
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlantis, FL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Roswell, GA
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Roswell, GA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Springfield, IL
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials